Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bicycle Therapeutics Ltd

BCYC
Current price
15.79 USD +0.02 USD (+0.13%)
Last closed 14.53 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 565 358 336 USD
Yield for 12 month -48.42 %
Week
Month
Year
BCYC
21.11.2021 - 28.11.2021

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets, as well as strategic collaboration with Bayer for developing Novel Targeted Radionuclide Therapies in Oncology. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Address: Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT

Analytics

WallStreet Target Price

48.92 USD

P/E ratio

Dividend Yield

Current Year

+14 463 000 USD

Last Year

+11 697 000 USD

Current Quarter

+5 352 000 USD

Last Quarter

+11 397 000 USD

Current Year

+14 463 000 USD

Last Year

+11 697 000 USD

Current Quarter

+5 352 000 USD

Last Quarter

+11 397 000 USD

Key Figures BCYC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -161 644 000 USD
Operating Margin TTM -949.12 %
PE Ratio
Return On Assets TTM -19.88 %
PEG Ratio
Return On Equity TTM -45.8 %
Wall Street Target Price 48.92 USD
Revenue TTM 24 830 000 USD
Book Value 9.82 USD
Revenue Per Share TTM 0.77 USD
Dividend Share
Quarterly Revenue Growth YOY 76.1 %
Dividend Yield
Gross Profit TTM -67 146 000 USD
Earnings Share -4.96 USD
Diluted Eps TTM -4.96 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BCYC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BCYC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BCYC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.5387
Price Sales TTM 22.7692
Enterprise Value EBITDA -0.2526
Price Book MRQ 1.3571

Financials BCYC

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BCYC

For 52 weeks

12.54 USD 33.49 USD
50 Day MA 16.84 USD
Shares Short Prior Month 4 350 643
200 Day MA 21.42 USD
Short Ratio 10.36
Shares Short 3 997 005
Short Percent 11.73 %